韩国国立忠北大学临床试验证实：岩藻多糖具有抗幽门螺杆菌活性
原标题：岩藻多糖FEMY-R7在小鼠和人体内具有抗幽门螺杆菌活性
①70%的胃溃疡患者、50-60%的慢性胃炎患者及90%的十二指肠溃疡患者体内都感染幽门螺杆菌，幽门螺杆菌也是慢性胃炎发展为胃癌的重要影响因素。
②岩藻多糖是来自于褐藻中的含硫酸基的多糖物质，具有广泛的生物活性，具有很强的清除幽门螺杆菌作用；
③本研究评价了岩藻多糖对小鼠和人体内幽门螺杆菌的清除及抑制作用；
④感染幽门螺杆菌的C57BL/6小鼠每天服用100mg/kg的岩藻多糖，持续两周；临床试验选取42位幽门螺杆菌患者，分为两组，试验组每天服用300mg岩藻多糖，持续8周。
⑤实验结果：服用岩藻多糖的小鼠幽门螺杆菌的根除率达83.3%；临床试验结果显示服用岩藻多糖组的尿素呼气试验基线值下降42%，同时血清中胃蛋白酶原（慢性萎缩性胃炎标志物）的含量显著下降。
⑥结论：岩藻多糖不但能直接清除体内幽门螺杆菌，还能改善胃功能。
延伸阅读
Lab Anim Res, 2014: 30(3), 131-135
Anti-Helicobacter pylori activities of FEMY-R7 composed of fucoidan and evening primrose extract in mice and humans
Abstract:
Helicobacter pylori-eliminating effects of FEMY-R7, composed of fucoidan and evening primrose extract, were investigated in mice and humans. Male C57BL/6 mice were infected with the bacteria by intragastric inoculation (1×109 CFU/mouse) 3 times at 2-day intervals, and simultaneously, orally treated twice a day with 10 or 100 mg/kg FEMY-R7 for 2 weeks. In Campylobcter-like organism-detection test, FEMY-R7 markedly reduced the urease-positive reactivity. In a clinical sudy, human subjects, confirmed to be infected with Helicobacter pylori, were orally administered twice a day with a capsule containing 150 mg FEMY-R7 for 8 weeks. FEMY-R7 significantly decreased both the Delta over baseline-value in urea breath test and the serum pepsinogens I and II levels. The results indicate that FEMY-R7 not only eliminates H. pylori from gastric mucosa of animals and humans, but also improves gastric function.
First Authors:
Tae-Su Kim
Correspondence:
Yun-Bae Kim
All Authors:
Tae-Su Kim, Ehn-Kyoung Choi, Jihyun Kim, Kyungha Shin, Sung-Pyo Lee, Youngjin Choi, Joseph H. Jeon, Yun-Bae Kim
2014-09-01 Article
